Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Genetic variant in the CYP17 gene and risk of premature coronary artery disease.

Agiannitopoulos K, Kyparissi A, Manginas A, Papamenzelopoulos S, Lamnissou K.

Hellenic J Cardiol. 2014 Mar-Apr;55(2):126-31.

2.

Genetic variation in the CYP17 gene and recurrent spontaneous abortions.

Litridis I, Kapnoulas N, Natisvili T, Agiannitopoulos K, Peraki O, Ntostis P, Pantos K, Lamnissou K.

Arch Gynecol Obstet. 2011 Feb;283(2):289-93. doi: 10.1007/s00404-009-1348-x. Epub 2010 Jan 13.

PMID:
20069306
4.

Association of apolipoprotein E polymorphism with myocardial infarction in Greek patients with coronary artery disease.

Kolovou G, Yiannakouris N, Hatzivassiliou M, Malakos J, Daskalova D, Hatzigeorgiou G, Cariolou MA, Cokkinos DV.

Curr Med Res Opin. 2002;18(3):118-24.

PMID:
12094820
5.

A polymorphism of the CYP17 gene related to sex steroid metabolism is associated with female-to-male but not male-to-female transsexualism.

Bentz EK, Hefler LA, Kaufmann U, Huber JC, Kolbus A, Tempfer CB.

Fertil Steril. 2008 Jul;90(1):56-9. Epub 2007 Sep 4.

PMID:
17765230
6.

CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China.

Madigan MP, Gao YT, Deng J, Pfeiffer RM, Chang BL, Zheng S, Meyers DA, Stanczyk FZ, Xu J, Hsing AW.

Int J Cancer. 2003 Nov 1;107(2):271-5. Review.

7.

CYP17 promoter polymorphism and breast cancer in Australian women under age forty years.

Spurdle AB, Hopper JL, Dite GS, Chen X, Cui J, McCredie MR, Giles GG, Southey MC, Venter DJ, Easton DF, Chenevix-Trench G.

J Natl Cancer Inst. 2000 Oct 18;92(20):1674-81.

PMID:
11036113
8.

Association of genetic polymorphisms of ER-alpha and the estradiol-synthesizing enzyme genes CYP17 and CYP19 with breast cancer risk in Chinese women.

Zhang L, Gu L, Qian B, Hao X, Zhang W, Wei Q, Chen K.

Breast Cancer Res Treat. 2009 Mar;114(2):327-38. doi: 10.1007/s10549-008-9998-0. Epub 2008 Jul 16.

PMID:
18629629
9.

CYP17 gene polymorphism and its association with high-risk north Indian breast cancer patients.

Chakraborty A, Murthy NS, Chintamani C, Bhatnagar D, Mohil RS, Sharma PC, Saxena S.

J Hum Genet. 2007;52(2):159-65. Epub 2007 Jan 18.

PMID:
17235448
10.

Cyp17 promoter variant associated with prostate cancer aggressiveness in African Americans.

Kittles RA, Panguluri RK, Chen W, Massac A, Ahaghotu C, Jackson A, Ukoli F, Adams-Campbell L, Isaacs W, Dunston GM.

Cancer Epidemiol Biomarkers Prev. 2001 Sep;10(9):943-7.

11.

Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect.

Habuchi T, Liqing Z, Suzuki T, Sasaki R, Tsuchiya N, Tachiki H, Shimoda N, Satoh S, Sato K, Kakehi Y, Kamoto T, Ogawa O, Kato T.

Cancer Res. 2000 Oct 15;60(20):5710-3.

12.

Association of serum sex steroid levels and bone mineral density with CYP17 and CYP19 gene polymorphisms in postmenopausal women in Turkey.

Yilmaz MB, Pazarbasi A, Guzel AI, Kocaturk-Sel S, Kasap H, Kasap M, Urunsak IF, Basaran S, Alptekin D, Demirhan O.

Genet Mol Res. 2011 Sep 9;10(3):1999-2008. doi: 10.4238/vol10-3gmr1204.

13.

The CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis.

Ye Z, Parry JM.

Mutagenesis. 2002 Mar;17(2):119-26.

PMID:
11880540
14.

CYP17 (T-34C) and CYP19 (Trp39Arg) polymorphisms and their cooperative effects on breast cancer susceptibility.

Tüzüner BM, Oztürk T, Kisakesen HI, Ilvan S, Zerrin C, Oztürk O, Isbir T.

In Vivo. 2010 Jan-Feb;24(1):71-4.

PMID:
20133979
15.

The prevalence of C807T mutation of glycoprotein Ia gene among young male survivors of myocardial infarction: a relation with coronary angiography results.

Lewandowski K, Swierczyńska A, Kwaśnikowski P, Elikowski W, Rzeźniczak M.

Kardiol Pol. 2005 Aug;63(2):107-13; discussion114.

PMID:
16136407
16.

CD14 promoter polymorphism (- 159C-->t) is not associated with myocardial infarction or coronary artery disease in patients with assumed high genetic risk.

Haberbosch W, Unkelbach K, Schuster D, Gardemann A, Tillmanns H, Hölschermann H.

Thorac Cardiovasc Surg. 2009 Oct;57(7):386-90. doi: 10.1055/s-0029-1185876. Epub 2009 Sep 30.

PMID:
19795323
17.

CYP17 5'-UTR MspA1 polymorphism and the risk of premenopausal breast cancer in a German population-based case-control study.

Verla-Tebit E, Wang-Gohrke S, Chang-Claude J.

Breast Cancer Res. 2005;7(4):R455-64. Epub 2005 Apr 12.

18.

The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer.

Haiman CA, Stampfer MJ, Giovannucci E, Ma J, Decalo NE, Kantoff PW, Hunter DJ.

Cancer Epidemiol Biomarkers Prev. 2001 Jul;10(7):743-8.

19.

No association of the 5' promoter region polymorphism of CYP17 gene with prostate cancer risk.

dos Santos A, Ribeiro ML, Mesquita JC, Carvalho-Salles AB, Hackel C.

Prostate Cancer Prostatic Dis. 2002;5(1):28-31. Review.

20.

Cyp17 genetic polymorphism in prostate cancer and benign prostatic hyperplasia.

Tigli H, Yazici H, Dalay N.

Res Commun Mol Pathol Pharmacol. 2003;113-114:307-14.

PMID:
15686129

Supplemental Content

Support Center